Diana M. Escolar, MD, FAAN
Chief Medical Officer
Diana is an experienced global medical leader who has been heavily involved in guiding the development of new therapies for rare diseases with a special focus on lysosomal and pediatric and adult neurogenetic disorders as both a board-certified neurologist and a biotech executive for more than 20 years. She previously served as chief medical officer at miRagen Therapeutics, a clinical-stage company developing microRNA therapeutics with leading indications in rare diseases, including rare T-cell lymphomas. Prior to working at miRagen, Diana was the chief medical officer of Akashi Therapeutics, Inc., the principal medical consultant for Acceleron Pharma’s muscular dystrophy program and a senior medical consultant and advisory board member for muscular dystrophy programs at Shire Plc. Diana was the principal medical consultant for Genzyme’s pivotal trial for Myozyme, an enzyme replacement therapy approved to treat adult-onset Pompe disease. In addition to her industry leadership, Dr. Escolar has served as associate professor of neurology at both Johns Hopkins University and George Washington University School of Medicine and Health Sciences, and was on the faculty at the Kennedy Krieger Institute. She has served as the co-founder and director of the Cooperative International Neuromuscular Research Group (CINRG) and as a steering committee member of the Spinal Muscular Atrophy Pilot Program funded by the National Institutes of Health (NIH). She served as director of the amyotrophic lateral sclerosis (ALS) clinic at George Washington University. As a faculty member at the Children’s National Hospital and Children’s Research Institute in Washington, D.C., she initiated and developed an international pediatric neuromuscular program, serving as director of the muscular dystrophy association (MDA) clinic and leading an international network conducting translational and clinical research in pediatric neurogenetic disorders. Diana earned her MD from the University of Buenos Aires and completed her neurology residency at Boston University Medical center and her fellowship in adult and pediatric neuromuscular diseases and electrophysiology at the Lahey Clinic and Boston Children’s Hospital, Harvard Medical School.
CloseToday is MPS Awareness Day (MPS II is also known as Hunter syndrome) and we want to recognize the incredible work that patient advocacy groups do year-round to support the Hunter syndrome community.
Learn more about Hunter syndrome and the patient advocacy groups’ efforts here: